Clinical trial
Safety of ALK Ragweed Tablet
NCT00330083 · ALK-Abelló A/S, Industry · Completed
Key facts
| NCT number | NCT00330083 |
|---|---|
| Title | Safety of ALK Ragweed Tablet |
| Official title | A RANDOMIZED, MULTIPLE DOSE, DOSE-ESCALATION, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE I TRIAL INVESTIGATING THE OPTIMAL SAFE DOSE OF ALK RAGWEED TABLET AMBROSIA ARTEMISIIFOLIA IN ADULT SUBJECTS WITH SEASONAL RHINOCONJUNCTIVITIS CAUSED BY RAGWEED POLLEN ALLERGY |
| Lead sponsor | ALK-Abelló A/S, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Allergy |
| Intervention type | Biological |
| Interventions | ALK Ragweed Tablet |
| Enrollment | 72 |
| Start date | May 1, 2006 |
| First posted | May 25, 2006 |
| Last update posted | Sep 21, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: